Application of at-line two-dimensional liquid chromatography–mass spectrometry for identification of small hydrophilic angiotensin I-inhibiting peptides in milk hydrolysates by van Platerink, Chris J. et al.
ORIGINAL PAPER
Application of at-line two-dimensional liquid
chromatography–mass spectrometry for identification
of small hydrophilic angiotensin I-inhibiting peptides
in milk hydrolysates
Chris J. van Platerink & Hans-Gerd M. Janssen &
Johan Haverkamp
Received: 17 October 2007 /Revised: 18 February 2008 /Accepted: 18 February 2008 /Published online: 9 April 2008
# The Author(s) 2008
Abstract A two-dimensional chromatographic method
with mass spectrometric detection has been developed for
identification of small, hydrophilic angiotensin I-inhibiting
peptides in enzymatically hydrolysed milk proteins. The
method involves the further separation of the poorly
retained hydrophilic fraction from a standard C18 re-
versed-phase column on a hydrophilic interaction liquid
chromatography (HILIC) column. The latter column is
specifically designed for the separation of hydrophilic
compounds. Narrow fractions collected from the HILIC
column were analysed for their angiotensin I-converting
enzyme (ACE) inhibiting potential in an at-line assay.
Fractions showing significant inhibition of ACE were
analysed by LC–MS for structure elucidation. With this
method the main peptides responsible for ACE-inhibition in
the hydrophilic part of a milk hydrolysate could be
determined. The ACE-inhibiting peptides RP, AP, VK,
EK, and EW explained more than 85% of ACE-inhibition
by the hydrophilic fraction.
Keywords Angiotensin-converting enzyme.
Bloodpressure-loweringpeptides.HPLC.MS.
Reversed-phase.HILIC
Introduction
Hypertension is one of the major health problems in the
western world. A variety of food ingredients that help to
reduce blood pressure have been described. Particularly
attractive are hydrolysed proteins from fermented milk
containing specific peptides that can inhibit the angiotensin
I-converting enzyme (ACE), an enzyme involved in blood-
pressure regulation [1–3]. For the development of opti-
mized anti-hypertensive food products, it is crucial to know
which specific peptide(s) in the complex protein hydroly-
sate is (are) responsible for the ACE-inhibition.
Identification of active ingredients in complex mixtures
is generally done using assay-guided repeated fractionation.
For the specific case of ACE-inhibiting peptides in milk-
protein hydrolysates often only part of the total activity of the
product can be assigned to specific peptides [4]. A significant
part of the remaining activity is present in fractions that are
poorly retained by the standard reversed-phase columns used
in the fractionation procedure. Nakamura et al. [1]f o r
example could only explain part of the activity of a casein
hydrolysate by the tri-peptides VPP and IPP eluting in one
of the later fractions. The remaining activity was present in
the unretained fraction. In our laboratory similar samples
were seen to have over 30% of the total activity in the
unretained fraction. Identification of the oligopeptides in this
fraction was not further pursued but would have been
extremely difficult because the fraction contains far too
many compounds for unambiguous activity assignment.
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present in the first-eluting fractions for reliable MS
identification. Similar situations are also described by other
authors [5–7]. In a previous investigation we presented a
new at-line method for the identification of ACE-inhibiting
(oligo)peptides in hydrolysed caseinate [4]. Approximately
70% of the activity of these samples was caused by peptides
nicely retained by the two reversed-phase columns used in
the fractionation. Twenty percent of the activity was present
in the hydrophilic fraction. The remaining 10% was caused
by a large number of peptides with low ACE-inhibiting
activity. Identification of the peptides in the hydrophilic
fraction was impossible due to the large number of peptides
present and the presence of co-eluting compounds, such as
salts and sugars, that resulted in severe suppression of
ionisation. Two reversed-phase columns were used in an at-
line 2D set-up to provide improved resolution of the very
complex mixture. Unfortunately, the highly hydrophilic
peptides escaped identification since they were unretained
on both columns. To identify the peptides responsible for the
ACE inhibition of the unretained hydrophilic fraction
improved chromatographic retention and separation is
required. Hydrophilic interaction chromatography (HILIC)
could be an attractive way of achieving this.
The use of HILIC for separation of hydrophilic sub-
stances such as proteins, peptides, and nucleic acids was
first described by Alpert in 1990 [8]. Since then HILIC has
been used for the separation of many different substances,
for example denaturants [9], polar oligomers [10], and
pharmaceutical ingredients [11]. Many publications can be
found describing the increased retention of hydrophilic
peptides on HILIC columns in comparison with reversed-
phase columns. A detailed review is published by Yoshida
[12]. Literature describing the application of reversed-phase
separation in combination with HILIC chromatography is
scarce. A notable exception is the compositional analysis of
an enzymatic protein hydrolysate obtained from acid-
deaminated wheat gluten by Schlichtherie-Cerny [13]. The
hydrolysate was first fractionated by GPC. The fraction
corresponding to a molecular weight range of 100–750Da
was then further fractionated by RPLC. Finally, the
peptides in the unretained peak from the RPLC column
were separated and characterised by HILIC–API-MS.
Using this method ten amino acids, eight di-peptides and
one tri-peptide, were identified in this fraction.
In this paper we describe the development of a method for
the identification of ACE inhibiting peptides in the poorly
retained fractions of a reversed-phase fractionation of an
enzymatically hydrolysed milk protein. The possibility of
improving chromatographic resolution by using a HILIC
separation as a second-dimension separation after the first
reversed-phase isolation is studied. The aim of the new
method is to extend the applicability of a previously
developed system for the identification of ACE-inhibiting
peptides in complex peptide mixtures such as protein hydro-
lysates [4]. The applicability of the method is demonstrated
by the identification of hydrophilic ACE-inhibiting peptides
in an enzymatically hydrolysed milk protein.
Experimental
Chemicals
The model peptides VPP, IPP, and LPP (purity >98%) were
purchased from Bachum (Dübendorf, Switzerland). All
other peptides were synthesised by JPT Peptide Technolo-
gies (Berlin, Germany). For HPLC analysis, acetonitrile,
formic acid, and trifluoroacetic acid were purchased from
Merck (Amsterdam, The Netherlands). Aqueous ammonia
(Merck) was used for neutralization of the HPLC fractions.
For instrument tuning PEG 300, PEG 600, and PEG 1000
were purchased from Sigma Chemicals (St Louis, MO,
USA). Ammonium acetate was obtained from Merck. For
the at-line assay angiotensin I-converting-enzyme (ACE)
and hippuryl–histidyl–leucine (HHL) were purchased from
Sigma–Aldrich Chemie (Zwijndrecht, The Netherlands).
PBS buffer was purchased from Gibco (Paisley, UK). The
hydrolysed milk powder was an enzymatically hydrolysed
milk protein obtained from Calpis (Tokyo, Japan).
Instrumentation
All peptide separations and identifications were performed
with a Waters Alliance 2795 HT HPLC coupled to a
Micromass QTOF-Ultima hybrid time-of-flight mass spec-
trometer equipped with a lock spray option for accurate
mass determination (Waters, Almere, The Netherlands).
Fractions were collected in polypropylene 300-μL 96-well
plates (Nunc, Roskilde, Denmark) using a Mark IV fraction
collector also from Waters. Solvent evaporation was
performed using an Ultravap 96-well evaporation device
(Porvair, Shepperton, UK). Quantification of HHL and HL
in the at-line assay was performed on the QTOF instrument
described above.
Two-dimensional analytical separation
The first-dimension reversed-phase separation was per-
formed on two serially connected 150 × 2.1mm Inertsil 5
ODS3 columns, particle size 5μm, operating in the gradient
mode (Varian, Middelburg, The Netherlands). The guard
column was a 20 × 3.9mm SymmetryShield RP8 column
packed with 5-μm particles (Waters, Etten-Leur, The
Netherlands). Mobile phase A consisted of 0.1% TFA in
Milli-Q water. Mobile phase B consisted of 0.1% TFA in
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After a 5min hold a linear gradient was started to 5% B in
15min, followed by a linear gradient to 70% B in 75min.
Finally, mobile phase composition was programmed to 99%
B in 1min and kept at 99% B for another 4min. At the end
of the gradient the eluent composition was reduced to 100%
A in 6min and the system was allowed to re-equilibrate for
14min. The total run time was 120min. The eluent flow rate
was 0.2mL min
−1 and the column temperature was 60°C.
In-house experiments revealed that at this temperature
isomeric peptides such as IPP and LPP are separated. UV
detection was performed at 215nm and 254nm. Fractions of
200μL were collected in 96-well plates. After neutralization
and solvent evaporation the residues were reconstituted in
50μL of an 80:20 mixture of solvents A and B for the
second-dimension HILIC analysis.
The second dimension HILIC analysis was performed on
a 150 × 2.1mm HILIC Atlantis column with a particle size
of 3μm (Waters, Etten-Leur, The Netherlands). Here
solvent A consisted of 0.1% formic acid in acetonitrile
and solvent B of 10mmol L
−1 aqueous ammonium acetate
solution+0.1% formic acid in Milli-Q water. The separation
was performed at 40°C, the maximum temperature speci-
fied by the manufacturer, and a flow rate of 0.2mL min
−1.
The initial eluent composition was 95% A. A linear
gradient was used to 70% B in 30min, followed by a linear
gradient to 90% B in 5min where it was kept for another
5min. At the end of the run the eluent was reduced to 95%
C in 2min. The eluent flow was then increased to 0.3mL
min
−1 in 1min. This flow rate was maintained for another
7min. Finally the flow was reduced to 0.2mL min
−1 in
1min. and the system was allowed to equilibrate for 3min.
The total run time was 54min. 45μL of each fraction
collected from the ODS3 column was injected. At the outlet
of the second dimension HILIC column fractions of 200μL
were collected in 96-well plates. The fractions were
neutralized, evaporated, and transferred to the activity assay
(next section).
At-line Matsui assay
ACE inhibition by the collected fractions was measured in a
96-well plate assay according to the at-line method
described in an earlier publication [1]. The method is based
on the conversion of hippuryl–histidyl–leucine (HHL) into
hippurate (H) and histidyl–leucine (HL) by the angiotensin
I-converting enzyme (ACE). Briefly, after evaporation of
the eluent the fractions were reconstituted in 50μL PBS
buffer and vortex mixed for 1min. This solution (40μL)
was used for the at-line assay. Percentage inhibition was
calculated from the peak areas of HHL and H at 280nm.
For the active fractions the remaining 10μL was used for
identification of the peptides.
Structural identification of ACEI peptides
Peptide identification was performed on the QTOF MS
instrument using HPLC–MS and MS–MS in the accurate
mass mode. Fractions collected after the second dimension
that showed activity were separated on the HILIC column
now coupled to the MS using the gradient described above.
The source and desolvation temperatures were 100°C and
300°C, respectively. The cone and desolvation gas flows
were 100L h
−1 and 800L h
−1, respectively. The capillary
voltage was 4kV and the cone voltage 35V. The collision
energy was 10eV in full-scan mode and 25eV in MS–MS
mode. The collision gas was argon and the analyser pressure
was 4 × 10
−5 mbar. In the lock spray probe a mixture of PEG
300, PEG 600, and PEG 1000 dissolved in 10mmol L
−1
ammonium acetate in methanol–water 1:1 (v/v) at concen-
trations of 0.01, 0.02, and 0.04μgm L
−1, respectively, was
used. The reference flow was 5μLm i n
−1. Spectra were
recorded at a resolution of 10,000. Masslynx software
(Waters) was used for data acquisition and evaluation.
Results and discussion
In a reversed-phase fractionation of a protein hydrolysate a
significant percentage of the activity can be present in the
unretained hydrophilic fraction. To be able to calculate the
contribution of this fraction of our milk hydrolysate to
the total activity, an ACE-inhibition profile of the entire
product was produced. To this end 20μL of a 20mg mL
−1
solution of the milk hydrolysate in solvent A was injected
on to the 300mm ODS3 column. Fractions of 200μL each
were collected from 0 to 65min, with an interval time of
1min, in a 96 well plate. The ACE inhibition of each
fraction was determined. Figure 1a shows the MS TIC of
the fermented milk and Fig. 1b shows the activity profile of
the same analysis. From the data in Fig. 1b it was calculated
that the hydrophilic compounds in fractions 6 to 15
represent approximately 25% of the total ACE inhibition.
MS–MS showed that the high activity in fractions 27 to 31
resulted from the known ACE inhibiting peptides IPP and
LPP. The activity in fractions 21 to 23 resulted from the
peptide VPP. These peptides have been identified to be the
main contributors to the ACE-inhibition of a Lactobacillus
helveticus-fermented milk [2] and represent 40% of the
total ACE inhibition. The remaining activity between
fractions 16 and 40 is most likely caused by a mixture of
ACE-inhibiting peptides of different chain lengths. This is
still under investigation. In the region from fraction 6 to
fraction 15 a large number of peptides co-elute and the
spectra of the fractions are highly complex. Figure 2, for
example, shows the mass spectrum of fraction 7 collected
from the first dimension ODS 3 columns and the ion traces
Anal Bioanal Chem (2008) 391:299–307 301of three of the ACE-inhibiting peptides discussed later in
this manuscript. At least 16 ions can be observed with
intensities above 10% of the base peak, all representing
different peptides. In order to be able to assign the
measured activity to one or more of these peptides a further
separation in an additional chromatographic dimension is
required. To achieve this, fractions collected from the first-
dimension ODS column were injected on the second
dimension HILIC column. Again 200-μL fractions were
collected in 96-well plates. After neutralization and evap-
oration the residues were reconstituted in 50μL Milli-Q
water. Of this, 40μL was used for ACE inhibition testing,
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Fig. 1 LC separation of a 20 mg mL
−1 solution of the milk hydrolysate powder on the ODS-3 reversed-phase column. a MS-TIC chromatogram.
b Activity profile. Error bars indicate the standard deviation (n=3). Fraction volume 200 μL
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Fig. 2 Mass spectrum of fraction 7 collected from the first-dimension ODS3 column
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Fig. 3 MS-TIC of fraction 7 from the ODS3 column analysed on the HILIC column. The inset shows the selected ion traces of three of the most
active peptides
Anal Bioanal Chem (2008) 391:299–307 303the remaining 10μL for MS identification. As an example
of the results of these experiments, Fig. 3 shows the TIC
chromatogram obtained from full-scanning analysis of
fraction 7 of the ODS3 columns, now separated on the
second dimension HILIC column. The TIC chromatogram
clearly shows that the composition of this fraction is indeed
very complex. To identify the peptide(s) responsible for the
ACE-inhibition, the fractions collected in the 96-well plate
were subjected to the ACE-inhibition assay. Figure 4
displays the activity distribution of ODS fraction 7. The
data in Fig. 4 are corrected for the background recorded
using a blank gradient, i.e. a gradient without injection.
Blank analysis of the HILIC column showed slightly
negative values compared with a reference of pure PBS.
The reason for these negative responses is still unknown.
The results in Fig. 4 clearly show the strong activity in
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Fig. 4 ACEI profile of fraction
7 from the ODS3 column ana-
lysed on the HILIC column
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304 Anal Bioanal Chem (2008) 391:299–307HILIC fractions 17 to 19 and somewhat lower activity in
fractions 12 to 16 from the HILIC column. LC–MS
separations were performed on these fractions and the MS
data were searched for peptides in the two active regions. In
Fig. 5 the mass spectrum of fraction 18 is given. In the
spectrum three abundant ions can be observed. A library
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Fig. 6 Three-dimensional dis-
play of the ACEI distribution
of the fractions collected from
the ODS3 column and the
HILIC column
Table 1 Peptides identified in fractions 6 to 15 of the ODS3 column, analysed on the HILIC column
elution
(min)
time
peptide
sequence
IC50
value
(μM)
literature
Literature
reference
Inhibition
at 20 μM
(%)
peak
area
(counts)
elution
time
(min)
peptide
sequence
value
(μM)
literature
Literature
reference
Inhibition
20 μM
(%)
peak
area
(counts)
11.64 F n.r. 83 16.34 FP 1215.7 13 n.m. 631
11.90 Y n.r. 2274 16.41 HSM n.r. 656
12.02 EI n.r. 38.2 2221 16.43 EPF n.r. 186
12.36 IE n.r. 3.7 4591 16.43 DKI n.r. 187
12.40 YP 720 13 n.m. 58 16.52 KY 1.63,7.8,13 16,13,17 n.m. 13
12.59 EV n.r. 25.4 622 16.66 VYP 288 13 125
12.59 VE n.r. 41.0 22 17.00 EW n.r. 65.1 1578
12.59 IP 129 13 17.7 100 17.22 VK 12.9 13 57.2 167
12.84 VP 575 13 45.9 801 17.23 ER n.r. n.m. 236
13.21 E n.r. n.m. 288 17.30 SGY n.r. 624
13.26 TE n.r. 26.0 344 17.35 ME n.r. 24.6 42
13.44 LQ n.r. 11.2 748 17.55 K n.r. n.m. 497
13.74 KP 16,22,30 13,15 33.7 144 17.61 EK n.r. 41.8 337
13.81 VNE n.r. 1378 17.84 RE n.r. n.m. 166
14.08 LN n.r. 14.7 271 17.86 KE n.r. 13.4 83
14.10 Q n.r. n.m. 511 17.89 KV 33 n.m. 235
14.10 QD n.r. n.m. 791 18.04 VVR n.r. 114
14.28 TDVEN n.r. 2019 18.08 HP n.r. 11.1 1427
14.50 PT n.r. 3.1 1001 18.18 KVP n.r. 45
14.56 NVP n.r. 2744 18.24 VPQ n.r. 505
14.61 YQ n.r. n.m. 36 18.63 RP 21,91,182 13 36.4 1340
14.64 SPP n.r. 335 18.97 PH n.r. 0.0 306
14.72 TQ n.r. 0.0 175 19.03 QP n.r. n.m. 402
14.86 AH n.r. 7.3 101 19.11 KP 16,22,30 13,15 33.6 144
14.91 PP 2284.7 18 0.0 1759 19.22 APK n.r. n.m. 266
15.01 AP 29,269 13,10 11.4 811 20.18 VRG n.r. n.m. 313
15.18 PQ n.r. 0.0 1041 20.47 HK n.r. 0.0 398
The sequences of the bold printed peptides were confirmed by MS–MS analyses of reference peptides, n.r., not reported in the literature; n.m., not
measured
Anal Bioanal Chem (2008) 391:299–307 305search and MS–MS measurements revealed that m/z
272.1721 represents the molecular ion of the di-peptide
RP (−0.7ppm), while m/z 253.1190 represents the molec-
ular ion of HP (−2.1ppm) and m/z 235.1305 the loss of
water from m/z 253.1190. Identification of the peptides in
the remaining fractions of the HILIC column showed that
fraction 7 of the first-dimension ODS3 column consisted of
three free amino acids, 19 di-peptides and 2 tri-peptides
while six compounds remained unidentified. The positively
identified amino acids were E, Q, and K and the di-peptides
were QD, KY, ER, RE, KP, HP, RP, AP, VK, EK, EW, and
PH. The di-peptides ET, TP, TQ, PQ, KV, KE, and HK and
the tri-peptides APK and VRG were tentatively identified.
Structure confirmation was based on elution time, measured
exact mass (error <5ppm) and MS–MS fragmentation
pattern compared with those of the model compounds.
Using this method the remaining hydrophilic fractions 5 to
15 collected from the ODS3 column were also analysed in
the 2D mode. In Fig. 6 a three-dimensional plot of the
activity distribution over the fractions of the two columns is
given. In total, five amino acids, 35 di-peptides, 13 tri-
peptides, one penta-peptide and 18 not yet identified
compounds were found. The identities of all amino acids
and the sequence of 27 di-peptides were again confirmed by
use of model compounds. Table 1 lists the sequences of the
identified peptides together with their reported IC50 values
and ACE inhibition data at 20μmol L
−1 established in house
(Foltz et al. manuscript in preparation). For peptides for
which no model compounds were available, identification
was based solely on the fragmentation pattern in MS–MS.
To verify whether the identified peptides indeed fully
explain the measured activity of the hydrophilic fraction the
concentration of all peptides should be determined. Next a
mixture should be prepared which is then analysed using
the two-dimensional method described in this article. The
ACE-inhibition profile of this mixture should be identical
with that of the sample. Such an experiment will hardly be
feasible because it requires the availability of all the
components. To estimate of the completeness of identifica-
tion, the contribution of each peptide was estimated from
the measured peak area and the IC50 value obtained from
literature or from unpublished in-house data. To estimate
the contribution of an individual peptide the following
relationship was used: CA ≈ Ap/IC50p. In this equation CA
represents the contribution of the peptide to the measured
ACE-inhibition, Ap the peak area, and IC50p the IC50 value
of the peptide. Clearly this proportionality equation is only
approximate as it assumes that the MS response for all
peptides is identical. When both the peak area and the IC50
value are taken into consideration it can be concluded that
the di-peptides AP, RP, VK, and EK are the main peptides
responsible for the measured ACE-inhibition of the hydro-
philic fractions 6 to 10 collected from the ODS3 column
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306 Anal Bioanal Chem (2008) 391:299–307(Fig. 7). In Fig. 8 the activities of all peptides in each
fraction are summarized and the profile is compared with
that of the measured profile. The two profiles are similar.
The differences between the graphs can be explained from
the fact that no correction was applied for differences in MS
responses of the various peptides.
The remaining fractions 11 to 15 of the ODS3 column
were analysed in the same way as fractions 6 to 10. These
analyses showed that the peptide EW is responsible for the
major part of the ACE-inhibition measured in these fractions.
In total, the five peptides identified in the fractions 6 to 15 are
responsible for approximately 85% of the activity measured
in the hydrophilic fractions. The most important contribution
is that of the di-peptide RP, which is responsible for 34%.
Together with the peptides VPP, IPP, and LPP now
approximately 65% of the total activity of the product has
beenexplained. The remaining 35% isdistributedover a large
number of peptides with relatively low overall activities.
When compiling the list of published IC50 values for the
peptides identified in this study in some cases large
differences were seen for the IC50 values of proline-
containing peptides in different publications. The reported
IC50 values for AP, for example, vary between 29 and
269 μmol L
−1 [14]. This large difference might be caused
by variations in the cis-to-trans ratio of the proline present
in synthetic model compounds as a result of differences in
the synthetic routes (Fmoc or Boc), as was shown for the
peptide DKIHP by Gómez-Ruiz [15]. In our calculations
the trans-Pro value of 29 μmol L
−1 for AP was used,
because trans-Pro is known to be dominant in natural
products [15]. Many of the identified di-peptides were
found in milk hydrolysates for the first time. For most of
the newly identified ACE active peptides it is actually the
first time they are reported at all. The long list of newly
identified peptides found here clearly demonstrates the
potential of the two dimensional separation approach of
HILIC and reversed-phase HPLC described here.
Conclusions
Two-dimensional liquid chromatography in combination
with mass spectrometry was successfully used for identifi-
cation of poorly retained peptides present in enzymatically
hydrolysed milk protein. A standard C18 reversed-phase
column was used for the first separation followed by a
second dimensional separation on a HILIC column. This
two-dimensional procedure significantly improves the
separation of hydrophilic peptides that elute almost unre-
tained on a reversed-phase column and co-elute with
numerous other compounds such as carbohydrates and
salts. These compounds suppress the MS ionization and
complicate identification. The method enabled the identifi-
cation of hydrophilic peptides in complex mixtures. In the
hydrophilic fraction of the milk hydrolysate investigated 71
compounds were found, including five free amino acids, 35
di-peptides, 12 tri-peptides, one penta-peptide, and 18 not
yet identified compounds. Five peptides, RP, AP, VK, EK,
and EW were responsible for approximately 85% of the
measured activity of the hydrophilic fraction; of these RP
made the highest contribution of 34%. None of the five
peptides has, to our knowledge, been reported earlier in
milk hydrolysates or related products such as yogurt or
cheese. Most of the peptides involved remained undetected
in single-dimensional chromatography.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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